TABLE 2.

Overall survival and progression-free survival estimates for different regimens added to chemotherapy.

Time/year	Pembrolizumb	Atezolizumab	Camrelizumb	Sintilimab	Sugemalimab	Tislelizumab	Toripalimab
Parametric models: Survival years based on FP and Cox-PH models
PFS: time-varying HRs
1	0.663	0.640	0.765	0.728	0.775	0.710	—
2	0.990	0.947	1.320	1.243	1.323	1.189	—
PFS:time-invariant HRs
1	0.568	0.523	0.683	0.622	0.695	0.627	0.617
2	0.820	0.699	1.200	0.981	1.248	1.001	0.967
OS: time-varying HRs
5	2.054	2.058	2.757	—	—	—	—
10	2.397	2.445	3.723	—	—	—	—
OS: time-invariant HRs
5	2.112	1.802	2.476	2.419	2.702	--	--
10	2.495	2.031	3.110	2.994	3.597	--	--
Nonparametric model: Aditional survival years (95% CI) based on RMST model
OS
0.98	1.02 (0.42–1.62)	−0.11 (0.66–0.44)	0.61 (0.04–1.18)	(0.19-1.65)	—	—	—
PFS
1.03	1.71 (1.11–2.31)	0.90 (0.37–1.43)	2.72 (1.06–3.39)	1.53 (0.91–2.15)	3.02 (2.11–3.94)	1.76 (0.83-2.70)	—

FP, fractional polynomial; PH, proportional hazards; RMST, restricted mean survival time